Longenesis

According to a recent meta-analysis, clinical trial recruitment takes up to 30% of the time of the clinical trial. Also, it is one of the major expenses of the research. It is always a challenge for Pharma companies and CRO’s to find and recruit patients according to a huge list of inclusion and exclusion criteria. Usually, only those patients are reachable for the particular company, who are visible within an existing network of their affiliated sites and clinical investigators. 

Our flagship product, Longenesis.Proteus serves as a showcase for biomedical datasets and patient cohorts enabling collaboration between clinical investigators, researchers, and pharma companies.

Lack of transparency limits collaboration and sponsorship opportunities. A low number of patients in the studied cohorts constrains statistical power and thus insights generated through the research. Longenesis.Proteus is able to change that.

Today medical research is highly fragmented. Similar studies are run by clinical investigators within hospitals around the globe and even in neighboring countries. Lack of transparency limits collaboration and sponsorship opportunities. A low number of patients in the studied cohorts constrains statistical power and thus insights generated through the research. This problem influences the total costs and time of clinical trial and at the end of the day it solves down whole the clinical research industry. 

Longenesis.Proteus allows CRO’s, Pharma companies and other research institutions to query according to their criteria, identify and reach for clinical trial recruitment patients cohorts worldwide. Moreover, every patient cohort published on the Longenesis.Proteus has a responsible and incentivized clinical investigator who has been threatening those patients for a while, somebody to whom these patients trust. At the same time, Longenesis.Proteus makes previous research and endorsements from colleagues visible for the particular clinical investigator. Thus, research institutions can not only easily identify specific patients based on their specific data points, but also reach them through a trustworthy and responsible person - trier physician. 

The ecosystem provided by Longenesis has several types of stakeholders: clinical investigators, researchers, biobanks, CRO's and Pharma companies. Clinical investigators receive the tool that can significantly increase their efficiency (in terms of time). According to a recent meta-analysis, clinical trial recruitment takes up to 30% of the time of the clinical trial, Longenesis eases this process. A researcher can find potential collaborators, with a needed cohort of patients, or with active research in the same field. Moreover, the researcher and his sponsor can monetize the data  that had been used during the research by providing it to the data acquirer (e.g. Pharma). 

In turn, Pharma receives the data and in some cases access to the patients with specific diseases, that decrease their costs for the trials. 

CRO's receive new clients depending on their specifications.

Longenesis.Proteus contributes to the clinical data analyzing sphere. First of all, Longenesis provides a consent management tool that allows sharing real-world data in a legal way. Secondly Longenesis.Proteus matches researchers and other stakeholders making the clinical trial process more cost effective. 

Longenesis uses a new approach for the clinical data transformation into a live-saving sharable assets. Our flagship product, Longenesis.Proteus serves as a showcase for biomedical datasets and patient cohorts enabling collaboration between clinical investigators, researchers, and pharma companies. By providing the added value to the clinical investigators, we create access to the patient cohorts (to its metadata) that could be used by other investigators or pharma. The consent tool developed by the company is secure, easy to use and applicable for the majority of the world's jurisdictions.

Longesis uses blockchain technology to provide security and traceability of the data sharing process. Longenesis has exclusive rights for Exonum blockchain usage in the healthcare sector. The Exonum platform leads the industry in transaction processing speed and scalability, while also bringing exceptional security to our project. With the Exonum ecosystem, we are building a powerful blockchain platform with smart contracts, anchoring to public blockchains and more.

Today the Exonum blockchain is widely used among government level organizations. The technology is already used by government land registry in Georgia, government e-auctions in Ukraine, academic certificates verification system in Russia. In turn blockchain technology itself, starts to have a wider implementation in the healthcare sphere. For example, U.S. based company BurstIQ, that helps healthcare companies safely and securely manage massive amounts of patient data, uses blockchain to improve the way medical data is shared and used.

A low number of patients in the studied cohorts constrains statistical power and thus insights generated through the research. Longenesis.Proteus allows clinical investigators to publish anonymized metadata on the datasets they have or on the patient cohorts that they have access to.  Potential collaborators can easily query and find disease and other criteria-specific patients and cohorts or datasets and contact their publisher free of charge. In this way, Longeneis increase investigators’ efficiency.  

At the same time, Longenesis.Proteus allows CRO’s, Pharma companies, and other research institutions to query according to their criteria, identify and reach for clinical trial recruitment patients cohorts worldwide. Once patient cohorts or biomedical datasets are identified, a researcher can easily contact the responsible person, who published them and recruit the patient in a cheaper way (than it was before). In this way, Longenesis decreases the costs of the drug discovery.

As we are working in B2B sector it is hard to give a precise figure about number of people who are using our product. Nevertheless, we can base on our customer size, for example Dubai based AI company G-42 plans to implement the consent management tool for 1 million patients in 2020. Basing on the 5% from market share in clinical data sphere, we are going to reach around 350 million people within the next 5 years.

Goals within one year: 

2M revenue pre-booked by Q1 2021

15 healthcare organisation integrations by Q2 2021

Considering the current pipeline of clients and assumption for growth, Longenesis plans to reach self-sufficiency level in May 2021.

Goals within five years: 

4M annual revenue in 2023

15 healthcare organisation integrations by Q4 2023

A major hub for prospective and on-demand consented data access for at least 35% of studies worldwide

Cutting patient recruitment times at least twice in 50% clinical trials conducted

Re-defining the way clinical data is shared

The main short-term barrier for us is a financial burden because we cannot scale the business with a large temp. In case of more fundamental barriers, there are some legal issues that differ in several regions. Also, many healthcare providers are conservative enough, that’s why there are barriers for new technology implementation.

Currently, we are closing our Series A round ($1.5 M) that will help us to scale our business model. Also, we are counting on public grants as this financial incentive will help us to boost our product as well. In order to solve the legal issues, Longenesis collaborates with leading legal companies in several regions. Also, we have key opinion leaders on our advisory board. 

Currently, there are 13 well-qualified employees in Longenesis. Sergey, the Co-Founder and CEO, manages the business development team that consists of Alex and Nikolay who are responsible for business analytics, strategy, and communication with clients and partners. Emil, the CTO, manages the development team: Ugis, Arnolds, Linda, Zlata, and the medical team: Jana, Svjatoslav, Agata, and Maksim. Ugis is a full-stack developer, Arnolds is a back-end developer while Linda is responsible for the design. Also, we have a representative from South Korea. 

The team behind Longenesis unites expertise from pharma, medical devices, entrepreneurship, blockchain, and data sciences. The management of the company has founded several medical device companies before starting Longenesis, all funded and functioning.

Overall, the management has raised >30M EUR into companies in the early and growth stages of their development. Sergey, specifically, has previously co-founded two venture-backed companies in the fields of medical devices and industrial engineering, having consulted more than 10 early-stage medical data/device companies in their growth stages.

Longenesis partners with Bitfury - blockchain unicorn - and Insilico Medicine - a pioneer in AI for drug discovery. The company is an exclusive handler of Exonum blockchain for healthcare projects – a framework developed by Bitfury for handling sensitive private data-related deployments. In turn, Insilico Medicine provides its insights about the Pharma industry and its needs. 

Longenesis runs a 2-stage business model:

1. SaaS approach for the consent management tool and for the access for Pharma to Longenesis.Proteus platform. SaaS approach considers a subscription-based fee, the fee bases on the size of the client. 

2. Royalty-based approach – Longenesis charges a 15% royalty from institutions generating revenue through Longenesis dashboard-enabled data showcasing to pharma.

Considering the current pipeline of clients and assumption for growth, Longenesis plans to reach self-sufficiency level in May 2021. In order to cover our cash-burn until this moment the company is closing Series A round, as well as is applying for several public grants, that will significantly help to the product development. 

MIT Solve provides both: funding opportunity and networking. The funding that is available will significantly contribute to the product development, on the other hand networking opens new opportunities for the further deployments. 

The main goals are related to funding and further deployment. However, as we are going to grow we definitely need to scale the team with new talents. Also there are several legal issues related to clinical data regulation in different markets, that’s why our legal partner in the new market will help us a lot. 

There are two perfect matches for us in the list of Solve Members: The Bill & Melinda Gates Foundation and Johnson and Johnson. Longenesis has a common vision with Bill & Melinda Gates Foundation as it also contributes to the healthcare system improvement through faster research. In turn, Johnson and Johnson provides a great opportunity for the pilot project, as Pharma companies are our target customers. 

Longenesis creates an infrastructure that enables legitimate real-world data sharing for healthcare institutions providing researchers with essential insights for clinical trial recruitment and new drug development, thus we match patients with unmet need with beneficial clinical trials and unlock huge amounts of biomedical data for research.

Beside that, We are developing disease-specific digital pre-screening and patient-education tools starting with Breast Cancer Digital pre-screening and Diabetes Monitoring Application.